Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells

Table 2 An overview of individual genes that belong to the 5 the GO-terms Nucleic acid binding/transcription factor/hydrolases/enzyme modulation/receptors and their expression in primary human AML cells – differences in gene expression between responders and non-responders

Nucleic acid binding transcription factor			Hydrolases		Enzyme modulation		Receptors
Increased*	Decreased		Increased	Decreased	Increased	Decreased	Increased	Decreased
AGAP3	AARSD1	MBTD1	ACP22	APOBEC3H	AGAP3	ARL16	OLFM4*	ADRA2C
ARAP3	APOBEC3H	MCART1	AFMID	ATP2A2	ARAP3	BIRC3	ST7	HP*
LMO4	ARAP3	MRPS15	LTF*	CDC14A	FBXO8	GNB4	TACSTD2*	MCHR2
NLRX1	DDX5I	MYCBP2	RNASE4	ELANE	MCF2L2	HP*		QRFPR
PCBP2	CDKN2AIP	PBX3		GNB4	PCBP2	MCYBP2		THADA
RBMI5	DDX51	PHAX		HP*	PI3	MYO3B		XPO1
RNASE4	FOXP1	SMC4		LRAP	RGL4*	PHKB
RPL30	HIST2H2AC	SNRNP70		SMC4	RNASE4
SNRPB	HOXA3*	TDRD1		TDP1	TP53BP2
TAF8	HOXA4	THOC		XRCC2
UBL4A	HOXA5*	XRCC2
WRN	LCOR	ZMAT3
	LRRF1P1	ZNF394
	MBD2

The classification of the genes refer to increased/decreased levels in responders compared with non-responders. Only those genes/probes with an annotation were included in the Panther analysis (and thereby also in this table) that is the basis for this classification
Increased or decreased levels means increased expression in responder patients
*Genes with significantly different expression also when comparing responders versus nonresponders (see Additional file 1: Table S5)

ISSN: 1471-2407